Silence Therapeutics plc (NASDAQ:SLN) Receives $45.00 Average Price Target from Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $45.00.

A number of research firms have recently commented on SLN. The Goldman Sachs Group started coverage on Silence Therapeutics in a research note on Tuesday, February 11th. They issued a “sell” rating and a $6.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Chardan Capital restated a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th.

Silence Therapeutics Stock Down 4.0 %

Shares of SLN opened at $4.32 on Thursday. Silence Therapeutics has a 52 week low of $4.06 and a 52 week high of $27.72. The stock has a market cap of $129.30 million, a P/E ratio of -2.75 and a beta of 1.05. The business’s 50 day moving average price is $5.58 and its 200-day moving average price is $11.65.

Hedge Funds Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in Silence Therapeutics in the fourth quarter valued at about $26,000. GAMMA Investing LLC grew its position in Silence Therapeutics by 609.2% during the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after buying an additional 5,233 shares during the period. Barclays PLC increased its holdings in Silence Therapeutics by 83.8% during the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after buying an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Silence Therapeutics during the 4th quarter worth $69,000. Finally, Virtus ETF Advisers LLC grew its position in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after acquiring an additional 6,098 shares during the period. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.